At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 385 enrolled
Drug / intervention
NES-E2 CVRdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Randomized Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of Nestorone® and Estradiol (NES-E2 CVR).
In Brief
A Phase 2 clinical trial evaluating NES-E2 CVR for Healthy Women and Female Contraception. Completed, enrolled 385 participants across 11 sites.
Detailed Summary
This will be a multi-site, open-label, randomized clinical trial. The investigators will randomize 300 eligible participants in a 1:1 ratio to two different treatment regimens that are to be followed when using a contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Women, Female Contraception
CountriesUnited States
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedFeb 2018
Primary CompletionAug 2021
Study CompletionDec 2021
TodayJul 2026
First PostedFeb 14, 2018
Enrollment StartFeb 12, 2018
Primary CompletionAug 28, 2021
Study CompletionDec 14, 2021
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.4 years ago
Interventions
NES-E2 CVRdrug
NES-E2 CVR